Nature Technology Corporation is a discovery-based bioengineering technology company, providing industry solutions for biopharmaceutical development: vectors; strains; processes; and products; including manufacturing and technology transfer. NTC specializes in services for manufacturing recombinant plasmids (gene therapeutics and DNA vaccines) and proteins.
Biopharmaceuticals are the fastest growing and most promising of new drug entities. Unlike small molecules, biologics are created in living cells and are designed to function in a highly specific manner. Rational design and advanced molecular technology (Gene Self Assembly, GENSA) has led to highly effective viral and non-viral vectors, designer proteins, gene therapeutics and DNA vaccines. Advanced strain engineering technology (Genome Mass Transfer, GMT) allows specialty microbial genomes to be created from existing host strains, incorporating the genetic and regulatory elements for highest-yield production and simplified processing. Process development creates and integrates essential engineering components of upstream (fermentation) and downstream (purification) technologies, resulting in highest-purity and greatest-yield products.
Tech transfer completes the cycle by integrating production technologies into client or CMO facilities for quality manufacturing of safe and effective biologics. NTC offers highly purified custom plasmid DNA manufacturing and recombinant protein production services.
Call to speak with an NTC specialist, today!
1(888) WIZ-BANG
|
Recent Publications/Press
• Autolytic strains for E. coli
• Antibiotic Free Plasmids
• NTC Waisman Team up
• Rig-1 Activating DNA Vaccines
• Vectors, Initial and Success Limiting
• NTC Publications
• When and Why to outsource
• Taq-Free DNA Polymerase
June 20, 2009
Coexpressed RIG-1 Agonist Enhances Antigen-specific Immune Responses to Influensa DNA Vaccine
NTC eRNA DNA Vaccinnes
2009
Plasmid DNA Production Combining Antibiotic-free Selection, Inducible High Yield Fermentation, and Novel Autolytic Purification
Carnes, AE, Hodgson, CP, Luke, JM, Vincent, JM, Williams, JA,, (Biotechnol. Bioeng., in press)
2009
Generic plasmid DNA production platform incorporating low metabolic burden seed-stock and fed-batch feermentation process
Batch fermentation processes DNA vaccines have tremendous potential for rapid deployment in pandemic applications, wherein a new antigen is plugged into a validated vector, and rapidly produced in a validated, fermentation - purification process.
April 3, 2009
Low Metabolic Burden Plasmid Production
Nature Technology’s
DNA Manufacturing Platform
Tackles Instability and Toxicity Issues
March 1, 2009
Strain Engineering by Genome Mass Transfer: Efficient Chromosomal Trait Transfer Method Utilizing Donor Genomic DNA and Recipient Recombineering Hosts
(Mol. Biotechnol., in press), DOI 10.1007/s12033-009-9177-5
2009
Plasmid DNA vaccine vector design: Impact on efficacy, safety and upstream production
Critical molecular and cellular biological factors impacting design of licensable DNA vaccine vectors that combine high yield and integrity during bacterial production with increased expression in mammalian cells are reviewed.
February 7, 2009
Meetings
Biochemical Engineering XVI
Past, Present, and Future of Biochemical Engineering, Burlington, Vermont, USA
July 5-9, 2009
Pattern Recognition Molecules and Immune Sensors of Pathogens, Banff, Alberta, Canada.
March 29 - April 3, 2009
ASGT-American Society for Gene Therapy: San Diego, CA,
May 27-30, 2009, (NTC Booth)
Partnering Opportunities
|
|
